Google
SLGL — SOL GEL TECHNOLOGIES LTD (Healthcare >> Biotechnology)
SLGL FAQ
What is SLGL's P/E ratio?
SOL GEL TECHNOLOGIES LTD (SLGL) currently trades at a P/E ratio of 20.94.
What is SLGL's ROE?
SOL GEL TECHNOLOGIES LTD reports a Return on Equity (ROE) of -2.03%.
What is SLGL's dividend yield?
SOL GEL TECHNOLOGIES LTD offers a dividend yield of 0.00%.
What is SLGL's Deepscope Quality Score?
Deepscope rates SLGL's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SLGL?
Deepscope's AI Timing Score for SLGL is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SLGL belong to?
SOL GEL TECHNOLOGIES LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 77.98
Price
3.61
(4.85%)
Day Change
|
|
|---|
SLGL, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 77.98 |
| PBV / Sector |
4.73 / 4.63
|
| Earning Per Share | -0.34 |
| PE / Sector |
20.94 / 17.43
|
| PEG or PE/Growth / Sector |
0.13 / 0.53
GREAT
|
| Average 1M Daily Value |
2.44 M
GREAT
|
| Average 1W Daily Value |
2.51 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:42 |
| Symbol | SLGL |
| Name | SOL GEL TECHNOLOGIES LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 3.27 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 243.11 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7 Golda Meir Street, Ness Ziona, Israel, 7403650
Phone: 972 8 931 3433
Website: https://www.sol-gel.com
Sector: Healthcare >> Biotechnology
Description: Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
